Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Technology appraisal guidance
Reference number: TA386
Published: 23 March 2016

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 177 KB)

Published:

28 April 2016

Final appraisal determination

Committee papers (PDF 1.24 MB)

Published:

25 February 2016
Final appraisal determination document (PDF 498 KB)

Published:

25 February 2016

Draft guidance

Appraisal consultation document (PDF 429 KB)

Published:

21 October 2015
Committee papers (PDF 7.15 MB)

Published:

21 October 2015

Equality impact assessment

Equality impact assessment (PDF 9.2 KB)

Published:

18 June 2015

Final scope

Final scope (PDF 102 KB)

Published:

18 June 2015

Final matrix

Final matrix (PDF 88 KB)

Published:

31 July 2015

Draft scope

Draft scope (PDF 110 KB)

Published:

09 February 2015

Provisional matrix

Provisional matrix (PDF 156 KB)

Published:

09 February 2015